» Articles » PMID: 18545145

Alpha-CTLA-4 MAb-associated Panenteritis: a Histologic and Immunohistochemical Analysis

Overview
Date 2008 Jun 12
PMID 18545145
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Monoclonal antibodies (mAbs) against the cytotoxic T lymphocyte antigen-4 (CTLA-4) molecule are used as an adjuvant to experimental tumor immunization protocols in the treatment of malignant melanomas and ovarian cancers. Aside from noted early therapeutic successes, a spectrum of adverse effects, including severe gastroenteritis, has been reported. We report herein our observations of 5 patients who developed severe gastrointestinal toxicity affecting the gastric, small intestinal, and colonic mucosa. The endoscopic findings were variable, ranging from normal to diffusely erythematous and ulcerated mucosa. The constant histologic findings included a lymphoplasmacytic expansion of the lamina propria with increase in intraepithelial lymphocytes. Increased epithelial apoptosis was also a distinctive feature. Cryptitis and glandular inflammation were observed in the colon, ileum, and stomach, whereas villous blunting was present in the ileal and duodenal mucosa. Immunohistochemical analysis revealed a marked increase of all T-cell subsets (CD3+, CD4+, and CD8+) and of CD4CD25 regulatory T cells. We conclude that the panenteritis associated with injection of alpha-CTLA-4 mAbs demonstrates histology resembling autoimmune enteropathy. Furthermore, although the pathogenesis of immune dysregulation after the infusion of alpha-CTLA-4 mAbs remains unclear, we suspect that the increased number of regulatory T cells in the gastrointestinal mucosa may play a role in the pathogenicity.

Citing Articles

Differential Disease Behavior of Immune-Mediated Colitis Among Different Types of Immune Checkpoint Inhibition.

Shatila M, Eshaghi F, Colli Cruz C, Machado A, Mathew A, Zhao D Target Oncol. 2025; .

PMID: 40038186 DOI: 10.1007/s11523-025-01135-7.


Drawbacks of immune checkpoint inhibition and rigorous management for immune-related adverse events along with a mathematical model to assess therapy success and optimum therapy duration and a strategy against tumor plasticity.

Hendekli C J Cancer Res Clin Oncol. 2023; 149(11):9375-9398.

PMID: 37076644 DOI: 10.1007/s00432-023-04718-x.


The multifaceted roles of common gut microbiota in immune checkpoint inhibitor-mediated colitis: From mechanism to clinical application.

Han X, Zang D, Liu D, Chen J Front Immunol. 2022; 13:988849.

PMID: 36189293 PMC: 9515466. DOI: 10.3389/fimmu.2022.988849.


Gut inflammation induced by drugs: Can pathology help to differentiate from inflammatory bowel disease?.

Herlihy N, Feakins R United European Gastroenterol J. 2022; 10(5):451-464.

PMID: 35633273 PMC: 9189468. DOI: 10.1002/ueg2.12242.


Histological Features of Celiac-Disease-like Conditions Related to Immune Checkpoint Inhibitors Therapy: A Signal to Keep in Mind for Pathologists.

Del Sordo R, Volta U, Lougaris V, Parente P, Sidoni A, Facchetti M Diagnostics (Basel). 2022; 12(2).

PMID: 35204486 PMC: 8871268. DOI: 10.3390/diagnostics12020395.